IDEAS home Printed from https://ideas.repec.org/a/plo/pmed00/1002181.html
   My bibliography  Save this article

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

Author

Listed:
  • Stefan Flasche
  • Mark Jit
  • Isabel Rodríguez-Barraquer
  • Laurent Coudeville
  • Mario Recker
  • Katia Koelle
  • George Milne
  • Thomas J Hladish
  • T Alex Perkins
  • Derek A T Cummings
  • Ilaria Dorigatti
  • Daniel J Laydon
  • Guido España
  • Joel Kelso
  • Ira Longini
  • Jose Lourenco
  • Carl A B Pearson
  • Robert C Reiner
  • Luis Mier-y-Terán-Romero
  • Kirsten Vannice
  • Neil Ferguson

Abstract

Background: Large Phase III trials across Asia and Latin America have recently demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 mo following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. We here report predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine vaccination with Dengvaxia in a range of transmission settings, as characterised by seroprevalence levels among 9-y-olds (SP9). These predictions were conducted for the World Health Organization to inform their recommendations on optimal use of this vaccine. Methods and Findings: The models adopted, with small variations, a parsimonious vaccine mode of action that was able to reproduce quantitative features of the observed trial data. The adopted mode of action assumed that vaccination, similarly to natural infection, induces transient, heterologous protection and, further, establishes a long-lasting immunogenic memory, which determines disease severity of subsequent infections. The default vaccination policy considered was routine vaccination of 9-y-old children in a three-dose schedule at 80% coverage. The outcomes examined were the impact of vaccination on infections, symptomatic dengue, hospitalised dengue, deaths, and cost-effectiveness over a 30-y postvaccination period. Case definitions were chosen in accordance with the Phase III trials. Conclusions: Dengvaxia has the potential to reduce the burden of dengue disease in areas of moderate to high dengue endemicity. However, the potential risks of vaccination in areas with limited exposure to dengue as well as the local costs and benefits of routine vaccination are important considerations for the inclusion of Dengvaxia into existing immunisation programmes. These results were important inputs into WHO global policy for use of this licensed dengue vaccine. Mark Jit and colleagues report findings from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia).Why Was This Study Done?: What Did the Researchers Do and Find?: What Do These Findings Mean?:

Suggested Citation

  • Stefan Flasche & Mark Jit & Isabel Rodríguez-Barraquer & Laurent Coudeville & Mario Recker & Katia Koelle & George Milne & Thomas J Hladish & T Alex Perkins & Derek A T Cummings & Ilaria Dorigatti & D, 2016. "The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study," PLOS Medicine, Public Library of Science, vol. 13(11), pages 1-19, November.
    • Handle: RePEc:plo:pmed00:1002181
    DOI: 10.1371/journal.pmed.1002181
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002181
    Download Restriction: no
    File URL: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002181&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pmed.1002181?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1995. "The friction cost method for measuring indirect costs of disease," Journal of Health Economics, Elsevier, vol. 14(2), pages 171-189, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Iris Arends & Ute Bültmann & Willem van Rhenen & Henk Groen & Jac J L van der Klink, 2013. "Economic Evaluation of a Problem Solving Intervention to Prevent Recurrent Sickness Absence in Workers with Common Mental Disorders," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-1, August.
    2. Simon Wieser & Bruno Horisberger & Sara Schmidhauser & Claudia Eisenring & Urs Brügger & Andreas Ruckstuhl & Jürg Dietrich & Anne Mannion & Achim Elfering & Özgür Tamcan & Urs Müller, 2011. "Cost of low back pain in Switzerland in 2005," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(5), pages 455-467, October.
    3. Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
    4. Chima, Reginald Ikechukwu & Goodman, Catherine A. & Mills, Anne, 2003. "The economic impact of malaria in Africa: a critical review of the evidence," Health Policy, Elsevier, vol. 63(1), pages 17-36, January.
    5. Tilling, C & Krol, M & Tsuchiya, A & Brazier, J & van Exel, J & Brouwer, W, 2009. "The impact of losses in income due to ill health: does the EQ-5D reflect lost earnings?," MPRA Paper 29837, University Library of Munich, Germany.
    6. Luis R Carrasco & Linda K Lee & Vernon J Lee & Eng Eong Ooi & Donald S Shepard & Tun L Thein & Victor Gan & Alex R Cook & David Lye & Lee Ching Ng & Yee Sin Leo, 2011. "Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 5(12), pages 1-9, December.
    7. Hoeijenbos, Margreet & Bekkering, Trudy & Lamers, Leida & Hendriks, Erik & van Tulder, Maurits & Koopmanschap, Marc, 2005. "Cost-effectiveness of an active implementation strategy for the Dutch physiotherapy guideline for low back pain," Health Policy, Elsevier, vol. 75(1), pages 85-98, December.
    8. Beata Gavurova & Miriama Tarhanicova, 2021. "Methods for Estimating Avoidable Costs of Excessive Alcohol Consumption," IJERPH, MDPI, vol. 18(9), pages 1-25, May.
    9. Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög, 2018. "Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 435-446, April.
    10. Pierre Kopp & Marysia Ogrodnik, 2017. "The social cost of drugs in France in 2010," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 883-892, September.
    11. Johan Jarl & Pia Johansson & Antonina Eriksson & Mimmi Eriksson & Ulf-G. Gerdtham & Örjan Hemström & Klara Selin & Leif Lenke & Mats Ramstedt & Robin Room, 2008. "The societal cost of alcohol consumption: an estimation of the economic and human cost including health effects in Sweden, 2002," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(4), pages 351-360, November.
    12. Juan Oliva & Félix Lobo & Julio López-Bastida & Néboa Zozaya & Rosa Romay, 2005. "Indirect costs of cervical and breast cancers in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 309-313, December.
    13. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1997. "Reply to Johanneson's and Karlsson's comment," Journal of Health Economics, Elsevier, vol. 16(2), pages 257-259, April.
    14. Brouwer, W. B. F. & Koopmanschap, M. A. & Rutten, F. F. H., 1999. "Productivity losses without absence: measurement validation and empirical evidence," Health Policy, Elsevier, vol. 48(1), pages 13-27, July.
    15. Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).
    16. Carmen Herrero & Juan D. Moreno‐Ternero, 2009. "Estimating production costs in the economic evaluation of health‐care programs," Health Economics, John Wiley & Sons, Ltd., vol. 18(1), pages 21-35, January.
    17. Brouwer, W. B. F. & van Exel, N. J. A. & Koopmanschap, M. A. & Rutten, F. F. H., 2002. "Productivity costs before and after absence from work: as important as common?," Health Policy, Elsevier, vol. 61(2), pages 173-187, August.
    18. Geke Romijn & Neeltje Batelaan & Jeroen Koning & Anton van Balkom & Aart de Leeuw & Friederike Benning & Leona Hakkaart van Roijen & Heleen Riper, 2021. "Acceptability, effectiveness and cost-effectiveness of blended cognitive-behavioural therapy (bCBT) versus face-to-face CBT (ftfCBT) for anxiety disorders in specialised mental health care: A 15-week ," PLOS ONE, Public Library of Science, vol. 16(11), pages 1-20, November.
    19. Siri Fauli & Geir Thue, 2008. "Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 221-228, August.
    20. Werner Brouwer & Samare Huls & Ayesha Sajjad & Tim Kanters & Leona Hakkaart-van Roijen & Job Exel, 2022. "In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era," PharmacoEconomics, Springer, vol. 40(1), pages 7-11, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pmed00:1002181. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosmedicine (email available below). General contact details of provider: https://journals.plos.org/plosmedicine/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.